Journal
CLINICAL BIOCHEMISTRY
Volume 44, Issue 8-9, Pages 576-581Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2011.03.128
Keywords
Autotaxin; Pancreatic cancer; Lysophosphatidic acid; Lysophospholipase D
Categories
Funding
- Grants-in-Aid for Scientific Research [22116004, 21390015, 22659013] Funding Source: KAKEN
Ask authors/readers for more resources
Objectives: To evaluate the potential clinical significance of serum autotaxin (ATX) level in patients with cancers of the digestive system. Design and methods: Serum ATX activity was measured as the lysophospholipase D activity in patients with cancer of the esophagus (n=8), stomach (n=18), colorectum (n=21), biliary tract (n=19), or pancreas (n=103) and in patients with benign pancreatic diseases (n=73). Results: Among patients with various cancers of digestive system, increased serum ATX activity was predominantly observed among pancreatic cancer patients. Serum ATX activity was not increased in patients with chronic pancreatitis or pancreatic cysts. In the diagnosis of pancreatic cancer, the area under the receiver operating curve for serum ATX activity was 0.541 (95% CI, 0.435-0.648) for men and 0.772 (95% CI, 0.659-0.885) for women. No significant correlation was observed between serum ATX activity and CEA, CA19-9 or Dupan2 levels. Conclusion: Serum ATX activity may be useful for identifying pancreatic cancer when used together with other serum markers of pancreatic cancer. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available